Mar. 20 at 8:30 AM
RBC Capital Markets highlighted a set of biotech names it views as more likely to draw takeover interest, including Revolution Medicines
$RVMD , Ascendis Pharma
$ASND , and Arrowhead Pharma
$ARWR along with a broader list of potential targets like Kymera Therapeutics
$KYMR , Rhythm Pharmaceuticals
$RYTM , Xenon Pharmaceuticals (XENE),and likely bidders.
“For acquirers, discussion of M&A does not drive the same upward inflection as for the smaller-cap biotechs that are often the targets,” the analysts noted, adding that it could be due to concerns over cash outlays, strategic fit, and other unfavorable views around the deal."
For stocks with already received specific acquisition proposals, solely in cash, check BARK, PRTH and PETS, all are trading with a discount by the proposed prices.
BARK for example trades at
$0.81 with two offers, at
$0.90 and
$1.10.
